Retatrutide vs AOD-9604: Next-Gen vs Legacy Weight Loss

Retatrutide is a novel triple receptor agonist (GLP-1/GIP/GCG) showing superiority over second-generation GLP-1s in clinical trials. AOD-9604 is a legacy HGH fragment with minimal evidence. This comparison shows the rapid evolution of weight loss therapeutics.

Mechanism: Agonist at GLP-1, GIP, and glucagon receptors simultaneously. Combines appetite suppression (GLP-1/GIP) with metabolic rate elevation (glucagon).

Clinical trials: REMODEL trial showed 24% weight loss (24.2 kg) over 48 weeks in obese patients. Superior to semaglutide's ~15-22%.

FDA status: Not yet approved (as of early 2026); in late-stage development. Expected approval within 2026.

Effect size: ~24% weight loss over 48 weeks (superior to GLP-1 monotherapy).

Side effects: GI side effects expected similar to GLP-1s (nausea, vomiting, diarrhea). May be slightly higher due to triple receptor activity.

Safety profile: Being evaluated in clinical trials; long-term data limited.

Cost (projected): $400-2,000/month (estimated; not yet approved/available).

Mechanism: HGH fragment; direct lipolysis stimulation.

Clinical evidence: One small pilot showing ~5 kg loss. No large trials published.

Effect size: ~5 kg over 12 weeks (weak evidence).

Status: Research compound; no regulatory approval.

Cost: $100-250/month.

Retatrutide advantages: - 24% weight loss (FDA trial) vs. 5% for AOD-9604 - Triple mechanism (stronger effect) vs. single mechanism - Large FDA trials vs. single small pilot for AOD-9604 - Approval imminent (2026) vs. AOD-9604's research status

Bottom line: Retatrutide is the future of weight loss peptides. It achieves superior weight loss vs. semaglutide and far exceeds AOD-9604's minimal evidence. AOD-9604 should not be considered for weight loss anymore given retatrutide's superiority.